A citation-based method for searching scientific literature

Yuhki Yokoyama, Hengrui Zhu, Jeong Heon Lee, Andrew V Kossenkov, Sherry Y Wu, Jayamanna M Wickramasinghe, Xiangfan Yin, Katherine C Palozola, Alessandro Gardini, Louise C Showe, Kenneth S Zaret, Qin Liu, David Speicher, Jose R Conejo-Garcia, James E Bradner, Zhiguo Zhang, Anil K Sood, Tamas Ordog, Benjamin G Bitler, Rugang Zhang. Cancer Res 2016
Times Cited: 83







List of co-cited articles
939 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
33

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
25

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
21

Super-enhancers in the control of cell identity and disease.
Denes Hnisz, Brian J Abraham, Tong Ihn Lee, Ashley Lau, Violaine Saint-André, Alla A Sigova, Heather A Hoke, Richard A Young. Cell 2013
21

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013
20

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Charles N Landen, Blake Goodman, Ashwini A Katre, Adam D Steg, Alpa M Nick, Rebecca L Stone, Lance D Miller, Pablo Vivas Mejia, Nicolas B Jennings, David M Gershenson,[...]. Mol Cancer Ther 2010
280
20


BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhenfeng Zhang, Pengfei Ma, Ying Jing, Ying Yan, Mei-Chun Cai, Meiying Zhang, Shengzhe Zhang, Huixin Peng, Zhi-Liang Ji, Wen Di,[...]. Theranostics 2016
61
22

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, Housheng Hansen He, Robert M Witwicki, Doris P Tabassum, Justin M Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan,[...]. Nature 2016
358
15

Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
Shu Zhang, Curt Balch, Michael W Chan, Hung-Cheng Lai, Daniela Matei, Jeanne M Schilder, Pearlly S Yan, Tim H-M Huang, Kenneth P Nephew. Cancer Res 2008
934
15


An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
Maria Giuseppina Baratta, Anna C Schinzel, Yaara Zwang, Pratiti Bandopadhayay, Christian Bowman-Colin, Jennifer Kutt, Jennifer Curtis, Huiying Piao, Laura C Wong, Andrew L Kung,[...]. Proc Natl Acad Sci U S A 2015
111
13

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
13

Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Ines A Silva, Shoumei Bai, Karen McLean, Kun Yang, Kent Griffith, Dafydd Thomas, Christophe Ginestier, Carolyn Johnston, Angela Kueck, R Kevin Reynolds,[...]. Cancer Res 2011
363
13

β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids.
S Condello, C A Morgan, S Nagdas, L Cao, J Turek, T D Hurley, D Matei. Oncogene 2015
120
13

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
12

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai,[...]. Lancet Haematol 2016
269
12

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.
Bjoern Chapuy, Michael R McKeown, Charles Y Lin, Stefano Monti, Margaretha G M Roemer, Jun Qi, Peter B Rahl, Heather H Sun, Kelly T Yeda, John G Doench,[...]. Cancer Cell 2013
485
12

CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Edmond Chipumuro, Eugenio Marco, Camilla L Christensen, Nicholas Kwiatkowski, Tinghu Zhang, Clark M Hatheway, Brian J Abraham, Bandana Sharma, Caleb Yeung, Abigail Altabef,[...]. Cell 2014
368
12

Epigenetic targeting of ovarian cancer stem cells.
Yinu Wang, Horacio Cardenas, Fang Fang, Salvatore Condello, Pietro Taverna, Matthew Segar, Yunlong Liu, Kenneth P Nephew, Daniela Matei. Cancer Res 2014
100
12

Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Lu Yang, Youyou Zhang, Weiwei Shan, Zhongyi Hu, Jiao Yuan, Jingjiang Pi, Yueying Wang, Lingling Fan, Zhaoqing Tang, Chunsheng Li,[...]. Sci Transl Med 2017
126
12

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Irfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke,[...]. Nature 2014
625
10

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.
Alison M Kurimchak, Claude Shelton, Kelly E Duncan, Katherine J Johnson, Jennifer Brown, Shane O'Brien, Rashid Gabbasov, Lauren S Fink, Yuesheng Li, Nicole Lounsbury,[...]. Cell Rep 2016
122
10

Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Jennifer A Mertz, Andrew R Conery, Barbara M Bryant, Peter Sandy, Srividya Balasubramanian, Deanna A Mele, Louise Bergeron, Robert J Sims. Proc Natl Acad Sci U S A 2011
805
10

Widespread transcription at neuronal activity-regulated enhancers.
Tae-Kyung Kim, Martin Hemberg, Jesse M Gray, Allen M Costa, Daniel M Bear, Jing Wu, David A Harmin, Mike Laptewicz, Kellie Barbara-Haley, Scott Kuersten,[...]. Nature 2010
10

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, Timo Kuschma, Stephan A Hahn, Deepak Vangala,[...]. Nat Med 2015
257
10

BET inhibitor resistance emerges from leukaemia stem cells.
Chun Yew Fong, Omer Gilan, Enid Y N Lam, Alan F Rubin, Sarah Ftouni, Dean Tyler, Kym Stanley, Devbarna Sinha, Paul Yeh, Jessica Morison,[...]. Nature 2015
348
9

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.
Zhiyuan Yang, Jasper H N Yik, Ruichuan Chen, Nanhai He, Moon Kyoo Jang, Keiko Ozato, Qiang Zhou. Mol Cell 2005
788
9

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.
Adam D Steg, Kerri S Bevis, Ashwini A Katre, Angela Ziebarth, Zachary C Dobbin, Ronald D Alvarez, Kui Zhang, Michael Conner, Charles N Landen. Clin Cancer Res 2012
258
9

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.
Camilla L Christensen, Nicholas Kwiatkowski, Brian J Abraham, Julian Carretero, Fatima Al-Shahrour, Tinghu Zhang, Edmond Chipumuro, Grit S Herter-Sprie, Esra A Akbay, Abigail Altabef,[...]. Cancer Cell 2014
280
9

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
David D Bowtell, Steffen Böhm, Ahmed A Ahmed, Paul-Joseph Aspuria, Robert C Bast, Valerie Beral, Jonathan S Berek, Michael J Birrer, Sarah Blagden, Michael A Bookman,[...]. Nat Rev Cancer 2015
592
9

Transcriptional Addiction in Cancer.
James E Bradner, Denes Hnisz, Richard A Young. Cell 2017
499
9

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait,[...]. Lancet Haematol 2016
276
9

Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.
Oumou Goundiam, Pierre Gestraud, Tatiana Popova, Thibault De la Motte Rouge, Virginie Fourchotte, David Gentien, Philippe Hupé, Véronique Becette, Claude Houdayer, Sergio Roman-Roman,[...]. Int J Cancer 2015
32
25

The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.
Debasish Raha, Timothy R Wilson, Jing Peng, David Peterson, Peng Yue, Marie Evangelista, Catherine Wilson, Mark Merchant, Jeff Settleman. Cancer Res 2014
166
9

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
William W Lockwood, Kreshnik Zejnullahu, James E Bradner, Harold Varmus. Proc Natl Acad Sci U S A 2012
264
8

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Philipp Rathert, Mareike Roth, Tobias Neumann, Felix Muerdter, Jae-Seok Roe, Matthias Muhar, Sumit Deswal, Sabine Cerny-Reiterer, Barbara Peter, Julian Jude,[...]. Nature 2015
330
8

Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Yan-Yi Jiang, De-Chen Lin, Anand Mayakonda, Masaharu Hazawa, Ling-Wen Ding, Wen-Wen Chien, Liang Xu, Ye Chen, Jin-Fen Xiao, William Senapedis,[...]. Gut 2017
120
8

Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Henry E Pelish, Brian B Liau, Ioana I Nitulescu, Anupong Tangpeerachaikul, Zachary C Poss, Diogo H Da Silva, Brittany T Caruso, Alexander Arefolov, Olugbeminiyi Fadeyi, Amanda L Christie,[...]. Nature 2015
221
8

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Hengrui Zhu, Fee Bengsch, Nikolaos Svoronos, Melanie R Rutkowski, Benjamin G Bitler, Michael J Allegrezza, Yuhki Yokoyama, Andrew V Kossenkov, James E Bradner, Jose R Conejo-Garcia,[...]. Cell Rep 2016
217
8

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.
Ilona Kryczek, Suling Liu, Michael Roh, Linhua Vatan, Wojciech Szeliga, Shuang Wei, Mousumi Banerjee, Yujun Mao, Jan Kotarski, Max S Wicha,[...]. Int J Cancer 2012
191
8

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
T Baba, P A Convery, N Matsumura, R S Whitaker, E Kondoh, T Perry, Z Huang, R C Bentley, S Mori, S Fujii,[...]. Oncogene 2009
313
8

Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1).
Shyh-Ming Yang, Adam Yasgar, Bettina Miller, Madhu Lal-Nag, Kyle Brimacombe, Xin Hu, Hongmao Sun, Amy Wang, Xin Xu, Kimloan Nguyen,[...]. J Med Chem 2015
36
19

A Phase Separation Model for Transcriptional Control.
Denes Hnisz, Krishna Shrinivas, Richard A Young, Arup K Chakraborty, Phillip A Sharp. Cell 2017
786
8

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
Christophe Ginestier, Min Hee Hur, Emmanuelle Charafe-Jauffret, Florence Monville, Julie Dutcher, Marty Brown, Jocelyne Jacquemier, Patrice Viens, Celina G Kleer, Suling Liu,[...]. Cell Stem Cell 2007
8

Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.
Brandt C Huddle, Edward Grimley, Cameron D Buchman, Mikhail Chtcherbinine, Bikash Debnath, Pooja Mehta, Kun Yang, Cynthia A Morgan, Siwei Li, Jeremy Felton,[...]. J Med Chem 2018
28
25

Coactivator condensation at super-enhancers links phase separation and gene control.
Benjamin R Sabari, Alessandra Dall'Agnese, Ann Boija, Isaac A Klein, Eliot L Coffey, Krishna Shrinivas, Brian J Abraham, Nancy M Hannett, Alicia V Zamudio, John C Manteiga,[...]. Science 2018
911
8

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Sibyl Bertrand, Aline Masse, Emmanuel Raffoux, Raphaël Itzykson, Marc Delord, Maria E Riveiro,[...]. Oncotarget 2015
176
7

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010
7

Structure and ligand of a histone acetyltransferase bromodomain.
C Dhalluin, J E Carlson, L Zeng, C He, A K Aggarwal, M M Zhou. Nature 1999
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.